Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by priceless2on Nov 25, 2019 10:45am

138 Views

Post# 30389194

RE:Hello jk

G1945V,

I see your point of view on clarifying the financing issue going forward but I am pretty sure after the CTAD conference we will know more details on the business side. IMO i think RVX and BP may be in close discussions on either a staged buyout?CVR deal or a partnership deal, If we don't hear anything on a PP after the CTAD ia think that is the case of a larger pending deal.....

Bullboard Posts

High Tide adds two stores to undervalued cannabis retail network